At the intersection of biotechnology and bold vision lies one of the most ambitious developments in longevity innovation this year: the official launch of LongGame, a venture capital fund dedicated entirely to extending human healthspan through cutting-edge science.
Founded by crypto pioneer Will Harborne and built with a team of elite thinkers and operators from the worlds of biotech, venture capital, and decentralized innovation, LongGame enters the longevity landscape with a refreshingly unapologetic ambition—to help people live not just longer lives, but longer healthy lives.
As investors increasingly turn their gaze toward healthspan as the next trillion-dollar opportunity, LongGame is making its debut with a sharp focus, a clear mission, and a $40 million fundraising goal. Here’s why this fund matters—and how it could shape the next decade of preventative and regenerative health.
From Crypto to Cellular Rejuvenation: The Story Behind LongGame
Will Harborne may be best known for building crypto and DeFi (decentralized finance) platforms like Bitfinex and rhino.fi, but his latest venture is less about digital assets and more about biological ones—our own bodies.
Like fellow crypto-native founders including Coinbase’s Brian Armstrong (who launched NewLimit), Harborne is now turning his entrepreneurial energy toward longevity biotechnology. But what sets LongGame apart is its unshakable belief in the feasibility—and urgency—of radical life extension.
At a time when many funds are cautious about investing in high-risk, long-term biotech ventures, LongGame is going all in. True to its name, the fund is positioning itself for a decades-long mission: to back therapies capable of increasing human lifespan by 10 years or more, and ideally, by 30+ yearsindex (20).
Harborne’s motivations are both personal and pragmatic. Inspired by bio-optimization pioneers like Bryan Johnson, he follows an intense health protocol himself. But as he admits, lifestyle changes only go so far. Real progress in extending human vitality will require interventions at the molecular and cellular level—something only advanced science and serious capital can deliver.
The Mission: Healthspan for All, Not Just the Elite
LongGame’s launch comes at a pivotal moment in the longevity field. Major breakthroughs in reprogramming, senolytics, and epigenetic therapies are on the horizon, but many companies remain underfunded due to the field’s perceived risks and long clinical timelines.
That’s precisely the gap LongGame aims to fill.
“Longevity shouldn’t just be about helping the wealthy live longer,” Harborne told Lifespan.io. “We want to ensure that these life-extending therapies are accessible to the masses. This is about helping society as a whole lead significantly longer and healthier lives”index (20).
It’s a refreshing perspective in a field that’s sometimes been accused of techno-elitism. The LongGame team understands that if longevity therapies are to succeed at scale, they need to be inclusive, affordable, and built on solid scientific foundations—not just hype.
What LongGame Will Invest In: Areas of Focus
LongGame’s investment thesis zeroes in on three primary areas that offer both profound health impact and near-term scientific traction:
1. Stem Cell Therapies
By replenishing or rejuvenating the body’s own regenerative toolkit, stem cell interventions hold promise in repairing tissues, reversing degeneration, and restoring function across organ systems. LongGame sees this space as a cornerstone of healthspan innovation.
2. Gene Editing and Genetic Medicine
With tools like CRISPR and base editors becoming more precise, gene editing opens doors to correcting aging-related mutations and enhancing resilience to disease. LongGame is particularly interested in companies targeting genetic drivers of mitochondrial decline, immune aging, and neurodegeneration.
3. Senolytics
Although opinions vary on their long-term efficacy, senolytics—drugs that selectively remove “zombie” cells—remain one of the first aging-targeted therapies to enter clinical trials. LongGame views them as a crucial stepping stone in building public and regulatory trust in longevity-focused treatments.
The fund is also exploring more radical areas like organ replacement, tissue engineering, and partial cellular reprogramming, though these are likely to feature more prominently in future iterations of the fund.
Bridging Biotech and DeSci: A Unique Angle
One of LongGame’s most distinctive elements is its openness to investing at the convergence of biotech and decentralized science (DeSci).
DeSci is a fast-growing movement that seeks to democratize research funding, incentivize open data sharing, and reduce reliance on traditional institutional gatekeepers. For Harborne, who has firsthand experience navigating Web3 paradigms, this represents an exciting structural innovation in how science is done.
By funding biotech startups that embrace open-source protocols, on-chain publishing, and community-driven governance models, LongGame hopes to accelerate both discovery and trust in a sector often bogged down by opacity and inefficiencyindex (20).
The Team: Scientists, Operators, and Visionaries
Any fund is only as good as its people, and LongGame has assembled an impressive lineup:
- Will Harborne (Founder & Managing Partner) – Former crypto founder and serial entrepreneur with a systems-thinking approach to aging and health.
- Chloe Northcott (Chief Operating Officer) – Previously at Geometry, brings deep operational expertise in scaling mission-driven organizations.
- Dr. Manish Chamoli (Chief Scientific Officer) – Former researcher at the Buck Institute for Research on Aging, a globally renowned hub for aging science.
- Sebastian Brunemeier (Special Advisor) – General Partner at Healthspan Capital and one of the most active investors in the longevity biotech spaceindex (20).
Together, this team bridges the worlds of science, capital, and execution—key ingredients for making real impact in a field as complex as longevity.
An Interview with Will Harborne: Why This, Why Now?
In a recent blitz interview, Harborne pulled back the curtain on LongGame’s strategy and philosophy:
Q: What’s the “secret formula” behind the fund?
“It’s our background in highly uncertain industries like crypto, where we learned how to evaluate risk and reward, paired with rigorous scientific diligence and a sharp eye on commercializability,” Harborne explainedindex (20).
Q: Are you really in this for the long haul?
“Absolutely. Solving aging isn’t quick, and our LPs know that. This fund is just the beginning—we plan a follow-up fund to invest in later-stage longevity companies as the field matures.”
Q: How do you measure something as bold as +30 years of life?
“Right now, it’s more of a mission anchor than a metric. Eventually, we’ll have statistical evidence. For now, we’re backing interventions that improve function and resilience in healthy populations—not just treating late-stage disease”index (20).
Why Longevity Biotech Needs Brave Capital
The longevity space is reaching a critical inflection point. Basic science has yielded dozens of promising pathways to target aging. But clinical translation remains slow—due in large part to a shortage of risk-tolerant capital.
Many biotech VCs shy away from aging-focused startups, citing long timelines, regulatory gray zones, and unclear commercial pathways.
LongGame flips that narrative.
By backing high-risk, high-reward interventions with clear short-term traction and long-term transformative potential, LongGame aims to carve a middle path—supporting companies that are credible today and revolutionary tomorrow.
It’s a strategy that could set a new precedent for investing not just in disease treatment, but in proactive human regeneration.
Looking Forward: A Vision for the Next Decade
In Harborne’s view, the next 10 years will be a golden era for longevity biotech—enabled not just by better science, but by better engineering and smarter capital.
Advances in AI-driven drug design, precision biomarker tracking, and genome-scale editing tools will unlock entirely new classes of healthspan-extending therapeutics. And with increased public awareness, longevity may soon be seen not as a luxury or niche, but as a pillar of 21st-century medicine.
LongGame wants to be at the center of that transformation.
Final Thoughts: Investing in the Future of Flourishing
Longevity isn’t just about living longer—it’s about thriving longer. It’s about retaining our strength, clarity, mobility, and joy well into the later decades of life. And to get there, we need more than vitamins and willpower. We need serious science—and serious support behind it.
With the launch of LongGame, a new chapter in longevity investing has begun. One that’s bold, inclusive, and willing to bet big on a better future.
If Harborne and his team are right, the best years of your life might still be ahead—and they’re not just investing in that vision. They’re building it.